213 related articles for article (PubMed ID: 14677527)
21. [CHARM study--new strategy for the treatment of heart failure].
Hasegawa H; Komuro I
Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
[TBL] [Abstract][Full Text] [Related]
22. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.
Hillege HL; Nitsch D; Pfeffer MA; Swedberg K; McMurray JJ; Yusuf S; Granger CB; Michelson EL; Ostergren J; Cornel JH; de Zeeuw D; Pocock S; van Veldhuisen DJ;
Circulation; 2006 Feb; 113(5):671-8. PubMed ID: 16461840
[TBL] [Abstract][Full Text] [Related]
23. [Benefits of candesartan in the treatment of symptomatic heart failure--CHARM programme].
Umemoto S; Matsuzaki M
Nihon Rinsho; 2004 Jan; 62(1):211-8. PubMed ID: 14737855
[TBL] [Abstract][Full Text] [Related]
24. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
O'Meara E; Clayton T; McEntegart MB; McMurray JJ; Piña IL; Granger CB; Ostergren J; Michelson EL; Solomon SD; Pocock S; Yusuf S; Swedberg K; Pfeffer MA;
Circulation; 2007 Jun; 115(24):3111-20. PubMed ID: 17562950
[TBL] [Abstract][Full Text] [Related]
25. Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy.
Colombo GL; Caruggi M; Ottolini C; Maggioni AP
Vasc Health Risk Manag; 2008; 4(1):223-34. PubMed ID: 18629370
[TBL] [Abstract][Full Text] [Related]
26. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
Yusuf S; Ostergren JB; Gerstein HC; Pfeffer MA; Swedberg K; Granger CB; Olofsson B; Probstfield J; McMurray JV;
Circulation; 2005 Jul; 112(1):48-53. PubMed ID: 15983242
[TBL] [Abstract][Full Text] [Related]
27. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.
Granger BB; Swedberg K; Ekman I; Granger CB; Olofsson B; McMurray JJ; Yusuf S; Michelson EL; Pfeffer MA;
Lancet; 2005 Dec; 366(9502):2005-11. PubMed ID: 16338449
[TBL] [Abstract][Full Text] [Related]
28. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors.
Granger CB; Ertl G; Kuch J; Maggioni AP; McMurray J; Rouleau JL; Stevenson LW; Swedberg K; Young J; Yusuf S; Califf RM; Bart BA; Held P; Michelson EL; Sellers MA; Ohlin G; Sparapani R; Pfeffer MA
Am Heart J; 2000 Apr; 139(4):609-17. PubMed ID: 10740141
[TBL] [Abstract][Full Text] [Related]
29. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program.
Olsson LG; Swedberg K; Ducharme A; Granger CB; Michelson EL; McMurray JJ; Puu M; Yusuf S; Pfeffer MA;
J Am Coll Cardiol; 2006 May; 47(10):1997-2004. PubMed ID: 16697316
[TBL] [Abstract][Full Text] [Related]
30. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme.
McMurray J; Ostergren J; Pfeffer M; Swedberg K; Granger C; Yusuf S; Held P; Michelson E; Olofsson B;
Eur J Heart Fail; 2003 Jun; 5(3):261-70. PubMed ID: 12798823
[TBL] [Abstract][Full Text] [Related]
31. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction.
Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Suzuki T; Kurabayashi M
J Am Coll Cardiol; 2005 Mar; 45(5):661-7. PubMed ID: 15734608
[TBL] [Abstract][Full Text] [Related]
32. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
McKelvie RS
J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
34. Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme.
O'Meara E; Solomon S; McMurray J; Pfeffer M; Yusuf S; Michelson E; Granger C; Olofsson B; Young JB; Swedberg K
Eur Heart J; 2004 Nov; 25(21):1920-6. PubMed ID: 15522471
[TBL] [Abstract][Full Text] [Related]
35. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program.
Desai AS; Swedberg K; McMurray JJ; Granger CB; Yusuf S; Young JB; Dunlap ME; Solomon SD; Hainer JW; Olofsson B; Michelson EL; Pfeffer MA;
J Am Coll Cardiol; 2007 Nov; 50(20):1959-66. PubMed ID: 17996561
[TBL] [Abstract][Full Text] [Related]
36. Improving outcomes in chronic heart failure.
Komajda M
Drugs Today (Barc); 2006 Dec; 42 Suppl C():29-36. PubMed ID: 17245479
[TBL] [Abstract][Full Text] [Related]
37. Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme.
O'Meara E; Lewis E; Granger C; Dunlap ME; McKelvie RS; Probstfield JL; Young JB; Michelson EL; Ostergren J; Carlsson J; Olofsson B; McMurray J; Yusuf S; Swedberg K; Pfeffer MA
Eur J Heart Fail; 2005 Jun; 7(4):650-6. PubMed ID: 15921807
[TBL] [Abstract][Full Text] [Related]
38. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme.
Chang SM; Granger CB; Johansson PA; Kosolcharoen P; McMurray JJ; Michelson EL; Murray DR; Olofsson B; Pfeffer MA; Solomon SD; Swedberg K; Yusuf S; Dunlap ME;
Eur J Heart Fail; 2010 Jul; 12(7):738-45. PubMed ID: 20418272
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin receptor blockers in heart failure.
Stergren J; McMurray JJ
J Renin Angiotensin Aldosterone Syst; 2003 Sep; 4(3):171-5. PubMed ID: 14608522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
